Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Bernhard, David Zahrieh, A. S. Coates, R. D. Gelber, M. Castiglione-Gertsch, E. Murray, J. F. Forbes, L. Perey, J. Collins, R. Snyder, C. M. Rudenstam, D. Crivellari, A. Veronesi, B. Thürlimann, M. F. Fey, K. N. Price, A. Goldhirsch, C. Hürny

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57 months tamoxifen. During the time with CMF toxicity (Tox), without symptoms and toxicity (TWiST), and following relapse (Rel), patients scored their QL indicators and a utility indicator for subjective health estimation between 'perfect' and 'worst' health. Scores were averaged within Tox, TWiST and Rel and transformed to utilities. Mean durations for the three transition times were weighted with utilities to obtain mean quality-adjusted TWiST (Q-TWiST). Patients receiving CMF reported significantly worse scores for most QL domains at month 3, but less hot flushes. After completing chemotherapy, there were no differences by treatment groups. Benefits evaluated by Q-TWiST favoured the additional chemotherapy. CMF provided 3 more months of Q-TWiST for patients with ER-negative tumours, but CMF provided no benefit in Q-TWiST for patients with ER-positive tumours. Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials.

Original languageEnglish (US)
Pages (from-to)1893-1901
Number of pages9
JournalBritish Journal of Cancer
Volume91
Issue number11
DOIs
StatePublished - Nov 29 2004
Externally publishedYes

Fingerprint

Methotrexate
Fluorouracil
Cyclophosphamide
Lymph Nodes
Quality of Life
Breast Neoplasms
Drug Therapy
Survival
Tamoxifen
Recurrence
Diagnostic Self Evaluation
Neoplasms
Clinical Trials
Health
Therapeutics

Keywords

  • Adjuvant therapy
  • Breast cancer
  • Q-TWiST
  • Quality of life
  • Quality-adjusted survival
  • Utility

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quantifying trade-offs : Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. / Bernhard, J.; Zahrieh, David; Coates, A. S.; Gelber, R. D.; Castiglione-Gertsch, M.; Murray, E.; Forbes, J. F.; Perey, L.; Collins, J.; Snyder, R.; Rudenstam, C. M.; Crivellari, D.; Veronesi, A.; Thürlimann, B.; Fey, M. F.; Price, K. N.; Goldhirsch, A.; Hürny, C.

In: British Journal of Cancer, Vol. 91, No. 11, 29.11.2004, p. 1893-1901.

Research output: Contribution to journalArticle

Bernhard, J, Zahrieh, D, Coates, AS, Gelber, RD, Castiglione-Gertsch, M, Murray, E, Forbes, JF, Perey, L, Collins, J, Snyder, R, Rudenstam, CM, Crivellari, D, Veronesi, A, Thürlimann, B, Fey, MF, Price, KN, Goldhirsch, A & Hürny, C 2004, 'Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer', British Journal of Cancer, vol. 91, no. 11, pp. 1893-1901. https://doi.org/10.1038/sj.bjc.6602230
Bernhard, J. ; Zahrieh, David ; Coates, A. S. ; Gelber, R. D. ; Castiglione-Gertsch, M. ; Murray, E. ; Forbes, J. F. ; Perey, L. ; Collins, J. ; Snyder, R. ; Rudenstam, C. M. ; Crivellari, D. ; Veronesi, A. ; Thürlimann, B. ; Fey, M. F. ; Price, K. N. ; Goldhirsch, A. ; Hürny, C. / Quantifying trade-offs : Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. In: British Journal of Cancer. 2004 ; Vol. 91, No. 11. pp. 1893-1901.
@article{ed0e5c5223274248b9509e94bf442a1a,
title = "Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer",
abstract = "We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57 months tamoxifen. During the time with CMF toxicity (Tox), without symptoms and toxicity (TWiST), and following relapse (Rel), patients scored their QL indicators and a utility indicator for subjective health estimation between 'perfect' and 'worst' health. Scores were averaged within Tox, TWiST and Rel and transformed to utilities. Mean durations for the three transition times were weighted with utilities to obtain mean quality-adjusted TWiST (Q-TWiST). Patients receiving CMF reported significantly worse scores for most QL domains at month 3, but less hot flushes. After completing chemotherapy, there were no differences by treatment groups. Benefits evaluated by Q-TWiST favoured the additional chemotherapy. CMF provided 3 more months of Q-TWiST for patients with ER-negative tumours, but CMF provided no benefit in Q-TWiST for patients with ER-positive tumours. Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials.",
keywords = "Adjuvant therapy, Breast cancer, Q-TWiST, Quality of life, Quality-adjusted survival, Utility",
author = "J. Bernhard and David Zahrieh and Coates, {A. S.} and Gelber, {R. D.} and M. Castiglione-Gertsch and E. Murray and Forbes, {J. F.} and L. Perey and J. Collins and R. Snyder and Rudenstam, {C. M.} and D. Crivellari and A. Veronesi and B. Th{\"u}rlimann and Fey, {M. F.} and Price, {K. N.} and A. Goldhirsch and C. H{\"u}rny",
year = "2004",
month = "11",
day = "29",
doi = "10.1038/sj.bjc.6602230",
language = "English (US)",
volume = "91",
pages = "1893--1901",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Quantifying trade-offs

T2 - Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

AU - Bernhard, J.

AU - Zahrieh, David

AU - Coates, A. S.

AU - Gelber, R. D.

AU - Castiglione-Gertsch, M.

AU - Murray, E.

AU - Forbes, J. F.

AU - Perey, L.

AU - Collins, J.

AU - Snyder, R.

AU - Rudenstam, C. M.

AU - Crivellari, D.

AU - Veronesi, A.

AU - Thürlimann, B.

AU - Fey, M. F.

AU - Price, K. N.

AU - Goldhirsch, A.

AU - Hürny, C.

PY - 2004/11/29

Y1 - 2004/11/29

N2 - We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57 months tamoxifen. During the time with CMF toxicity (Tox), without symptoms and toxicity (TWiST), and following relapse (Rel), patients scored their QL indicators and a utility indicator for subjective health estimation between 'perfect' and 'worst' health. Scores were averaged within Tox, TWiST and Rel and transformed to utilities. Mean durations for the three transition times were weighted with utilities to obtain mean quality-adjusted TWiST (Q-TWiST). Patients receiving CMF reported significantly worse scores for most QL domains at month 3, but less hot flushes. After completing chemotherapy, there were no differences by treatment groups. Benefits evaluated by Q-TWiST favoured the additional chemotherapy. CMF provided 3 more months of Q-TWiST for patients with ER-negative tumours, but CMF provided no benefit in Q-TWiST for patients with ER-positive tumours. Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials.

AB - We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57 months tamoxifen. During the time with CMF toxicity (Tox), without symptoms and toxicity (TWiST), and following relapse (Rel), patients scored their QL indicators and a utility indicator for subjective health estimation between 'perfect' and 'worst' health. Scores were averaged within Tox, TWiST and Rel and transformed to utilities. Mean durations for the three transition times were weighted with utilities to obtain mean quality-adjusted TWiST (Q-TWiST). Patients receiving CMF reported significantly worse scores for most QL domains at month 3, but less hot flushes. After completing chemotherapy, there were no differences by treatment groups. Benefits evaluated by Q-TWiST favoured the additional chemotherapy. CMF provided 3 more months of Q-TWiST for patients with ER-negative tumours, but CMF provided no benefit in Q-TWiST for patients with ER-positive tumours. Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials.

KW - Adjuvant therapy

KW - Breast cancer

KW - Q-TWiST

KW - Quality of life

KW - Quality-adjusted survival

KW - Utility

UR - http://www.scopus.com/inward/record.url?scp=19944428970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428970&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602230

DO - 10.1038/sj.bjc.6602230

M3 - Article

C2 - 15545973

AN - SCOPUS:19944428970

VL - 91

SP - 1893

EP - 1901

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -